The Claim
The principle of pathologically activated therapeutics (PAT) aligns with the earlier RADA concept by targeting drug action exclusively during pathological states characterized by receptor overstimulation, such as prolonged glutamate elevation in ischemic brain tissue.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
This idea is about a smart drug that only turns on when the brain is damaged and flooded with too much glutamate—like a safety switch that avoids messing with healthy brain cells.
See the scientific wording
The principle of pathologically activated therapeutics (PAT) aligns with the earlier RADA concept by targeting drug action only during pathological states of receptor overstimulation, such as prolonged glutamate elevation in ischemic brain tissue.
What the research says
1 studyStudy: Receptor abuse-dependent antagonism for neuroprotection
The study created a drug that only turns off harmful glutamate signals during brain injury, not during normal brain activity — exactly what the claim says PAT should do.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.